FDA Approves Johnson & Johnson’s RYBREVANT FASPRO for Certain HNSCC Patients

The FDA granted accelerated approval to Johnson & Johnson for RYBREVANT FASPRO, co-formulated with Halozyme’s ENHANZE, for certain adults with recurrent or metastatic HNSCC after platinum-based chemotherapy and anti-PD-(L)1 treatment. HPV-associated oropharyngeal cancer is excluded.